open access

Vol 84, No 7 (2013)
ARTICLES
Get Citation

Quercetin inhibits proliferation and increases sensitivity of ovarian cancer cells to cisplatin and paclitaxel

Adam Maciejczyk, Paweł Surowiak
DOI: 10.17772/gp/1609
·
Ginekol Pol 2013;84(7).

open access

Vol 84, No 7 (2013)
ARTICLES

Abstract

Introduction: Due to frequent diagnosis of ovarian cancer at an advanced clinical stage, in most cases surgical debulking is followed by chemotherapy. The principal cause of therapeutic failure involves incomplete surgery and resistance of neoplastic cells to chemotherapy. A search continues for substances which would overcome resistance to treatment and, as a result, would increase efficacy of the applied treatment. Quercetin represents one of more interesting compounds, which at present in subjected to several tests. Material and methods: Studies were performed on in vitro sensitivity of human ovarian cancer cell lines, SKOV-3, EFO27, OVCAR-3 and A2780P to low doses of quercetin and on the effect exerted by quercetin on sensitivity of the cell lines to cisplatin and pactitaxel. Results: The experiments proved that the studied cells of ovarian cancer manifest a similar sensitivity to quercetin. Following incubation of the cells with two distinct concentrations of quercetin and the studied cytostatic agents all the cells lines were found to significantly increase their sensitivity to pactitaxel In cases of two cell lines, OVCAR-2 and A2780P, they also significantly increased their sensitivity to cisplatin. Discussion: Our results demonstrated suitability of low quercetin doses (achievable using oral administration) as a substance which increases sensitivity of ovarian cancer cells to cisplatin and paclitaxel. The value of quercetin include its wide accessibility, efficacy and a broad range of activity but also its low toxicity, as compared to other examined compounds. Conclusions: Used in low doses, quercetin increases chemosensitivity of ovarian cancer cells.

Abstract

Introduction: Due to frequent diagnosis of ovarian cancer at an advanced clinical stage, in most cases surgical debulking is followed by chemotherapy. The principal cause of therapeutic failure involves incomplete surgery and resistance of neoplastic cells to chemotherapy. A search continues for substances which would overcome resistance to treatment and, as a result, would increase efficacy of the applied treatment. Quercetin represents one of more interesting compounds, which at present in subjected to several tests. Material and methods: Studies were performed on in vitro sensitivity of human ovarian cancer cell lines, SKOV-3, EFO27, OVCAR-3 and A2780P to low doses of quercetin and on the effect exerted by quercetin on sensitivity of the cell lines to cisplatin and pactitaxel. Results: The experiments proved that the studied cells of ovarian cancer manifest a similar sensitivity to quercetin. Following incubation of the cells with two distinct concentrations of quercetin and the studied cytostatic agents all the cells lines were found to significantly increase their sensitivity to pactitaxel In cases of two cell lines, OVCAR-2 and A2780P, they also significantly increased their sensitivity to cisplatin. Discussion: Our results demonstrated suitability of low quercetin doses (achievable using oral administration) as a substance which increases sensitivity of ovarian cancer cells to cisplatin and paclitaxel. The value of quercetin include its wide accessibility, efficacy and a broad range of activity but also its low toxicity, as compared to other examined compounds. Conclusions: Used in low doses, quercetin increases chemosensitivity of ovarian cancer cells.
Get Citation

Keywords

quercetin, ovarian cancer, cisplatin, Paclitaxel, chemoresistance

About this article
Title

Quercetin inhibits proliferation and increases sensitivity of ovarian cancer cells to cisplatin and paclitaxel

Journal

Ginekologia Polska

Issue

Vol 84, No 7 (2013)

DOI

10.17772/gp/1609

Bibliographic record

Ginekol Pol 2013;84(7).

Keywords

quercetin
ovarian cancer
cisplatin
Paclitaxel
chemoresistance

Authors

Adam Maciejczyk
Paweł Surowiak

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl